# Pozelimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pozelimab

> The next catalyst for pozelimab, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is its topline data readout, Jul to Oct 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | pozelimab |
| Codes | REGN3918 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | Age-related Macular Degeneration (AMD), [Paroxysmal Nocturnal Hemoglobinuria](https://sec-api.dev/indications/paroxysmal-nocturnal-hemoglobinuria) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Age-related Macular Degeneration (AMD); Geographic Atrophy (GA).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06541704 (A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06541704

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Age-related Macular Degeneration (AMD); Geographic Atrophy (GA).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06541704 (A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06541704

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Paroxysmal Nocturnal Hemoglobinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05744921 (A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-10 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05744921

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Paroxysmal Nocturnal Hemoglobinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05744921 (A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-10 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05744921

### Jan to Apr 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Paroxysmal Nocturnal Hemoglobinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07154745 (A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07154745

### January 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Paroxysmal Nocturnal Hemoglobinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07154745 (A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07154745

## Same indication

- [Voydeya (danicopan)](https://sec-api.dev/pdufa/danicopan) (AZN)
- [FABHALTA® (iptacopan)](https://sec-api.dev/pdufa/iptacopan) (NVS)
- [Oms906 study drug](https://sec-api.dev/pdufa/oms906-study-drug) (OMER)
- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)

Calendar months: [July 2028](https://sec-api.dev/fda-calendar/2028-07), [October 2028](https://sec-api.dev/fda-calendar/2028-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pozelimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pozelimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pozelimab

```bibtex
@misc{secapidev_pdufa_pozelimab_20261116,
  title        = {Pozelimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pozelimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pozelimab_20261116","title":"Pozelimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pozelimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
